{"id":915438,"date":"2025-12-02T16:43:08","date_gmt":"2025-12-02T21:43:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/"},"modified":"2025-12-02T16:43:08","modified_gmt":"2025-12-02T21:43:08","slug":"fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/","title":{"rendered":"FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit"},"content":{"rendered":"
\n

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY.<\/p>\n

Thane Wettig, Chief Executive Officer of\u00a0FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11\u00a0at\u00a012:15 PM ET\u00a0at the\u00a0Sofitel New York.<\/p>\n

FibroGen\u2019s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Oppenheimer.<\/p>\n

\n About\u00a0FibroGen<\/strong>
\n
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (\u7231\u745e\u5353\u00ae, EVRENZO\u2122) is currently approved in\u00a0Europe,\u00a0Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the\u00a0U.S.\u00a0FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit\u00a0www.fibrogen.com<\/a>.\u00a0<\/strong><\/p>\n

\n For Investor Inquiries:<\/strong>
\n
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of\u00a0FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11\u00a0at\u00a012:15 PM ET\u00a0at the\u00a0Sofitel New York. FibroGen\u2019s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Oppenheimer. About\u00a0FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (\u7231\u745e\u5353\u00ae, EVRENZO\u2122) is currently approved … <\/p>\n

Continue reading “FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915438","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of\u00a0FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11\u00a0at\u00a012:15 PM ET\u00a0at the\u00a0Sofitel New York. FibroGen\u2019s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Oppenheimer. About\u00a0FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (\u7231\u745e\u5353\u00ae, EVRENZO\u2122) is currently approved … Continue reading "FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T21:43:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU2NiM3MzAyNTM0IzIwMDc5NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit\",\"datePublished\":\"2025-12-02T21:43:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/\"},\"wordCount\":242,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTU2NiM3MzAyNTM0IzIwMDc5NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/\",\"name\":\"FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTU2NiM3MzAyNTM0IzIwMDc5NjM=\",\"datePublished\":\"2025-12-02T21:43:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTU2NiM3MzAyNTM0IzIwMDc5NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTU2NiM3MzAyNTM0IzIwMDc5NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/","og_locale":"en_US","og_type":"article","og_title":"FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - Market Newsdesk","og_description":"SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of\u00a0FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11\u00a0at\u00a012:15 PM ET\u00a0at the\u00a0Sofitel New York. FibroGen\u2019s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Oppenheimer. About\u00a0FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (\u7231\u745e\u5353\u00ae, EVRENZO\u2122) is currently approved … Continue reading \"FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-02T21:43:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU2NiM3MzAyNTM0IzIwMDc5NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit","datePublished":"2025-12-02T21:43:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/"},"wordCount":242,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU2NiM3MzAyNTM0IzIwMDc5NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/","name":"FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU2NiM3MzAyNTM0IzIwMDc5NjM=","datePublished":"2025-12-02T21:43:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU2NiM3MzAyNTM0IzIwMDc5NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTU2NiM3MzAyNTM0IzIwMDc5NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-to-present-at-the-oppenheimer-movers-in-rare-disease-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915438"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915438\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}